Compositions and methods of sphingosine kinase inhibitors for use thereof in cancer therapy

Abstract

The present invention relates to Sphingosine kinase inhibitors that are useful for treating various cancers. The invention specifically relates to compositions and methods of SPK inhibitors, including siRNAs, which specifically block gene expression of SPK and induce apoptosis in a variety of cancers.

1 . A composition comprising siRNA that specifically blocks the expression of sphingosine kinase and induces apoptosis in more than one type of cancer cell, wherein said cancer cell is a breast, prostate, colorectal, lung, bladder, head and neck, intestine, ovarian, skin or the like. 
     
     
         2 . The composition according to  claim 1 , wherein said cancer cell is in a mammal. 
     
     
         3 . The composition according to  claim 1 , wherein said siRNA comprises 19-25 oligonucleotides. 
     
     
         4 . The composition according to  claim 3 , wherein said oligonucleotide sequence is double stranded and comprises the sense sequence of SEQ ID NO 1 and antisense sequence of SEQ ID NO 2. 
     
     
         5 . The composition according to  claim 4 , wherein said sense sequence is SEQ ID NO 3 and antisense sequence is SEQ ID NO 4. 
     
     
         6 . A therapeutic agent comprising siRNA, that specifically inhibits the expression of sphingosine kinase and induces apoptosis in more than one type of cancer cell, wherein said cancer cell is a breast, prostate, colorectal, lung, bladder, head and neck, intestine, ovarian, skin or the like. 
     
     
         7 . The therapeutic agent according to  claim 6  wherein siRNA comprises 19-25 oligonucleotides. 
     
     
         8 . The therapeutic agent according to  claim 6 , wherein said siRNA is double stranded and comprises the sense sequence of SEQ ID NO: 1 and antisense sequence of SEQ ID NO: 2. 
     
     
         9 . The therapeutic agent according to  claim 6 , wherein said siRNA is double stranded and comprises the sense sequence of SEQ ID NO: 3 and antisense sequence of SEQ ID NO: 4. 
     
     
         10 . A composition comprising siRNA with a sense sequence comprising SEQ ID NO: 1 and an antisense sequence comprising SEQ ID NO: 2, and wherein said composition induces apoptosis in a variety of cancer cells. 
     
     
         11 . A composition comprising siRNA with a sense sequence comprising SEQ ID NO: 3 and an antisense sequence comprising SEQ ID NO: 4, and wherein said composition induces apoptosis in a variety of cancer cells. 
     
     
         12 . The composition according to  claim 10 , wherein said cancer cell is a breast, prostate, colorectal, lung, bladder, colorectal, head and neck, intestine, ovarian, skin or the like. 
     
     
         13 . The composition according to  claim 11 , wherein said cancer cell is a breast, prostate, colorectal, lung, bladder, colorectal, head and neck, intestine, ovarian, skin or the like. 
     
     
         14 . A therapeutic agent comprising a composition comprising siRNA with a sense sequence comprising SEQ ID NO: 1 and an antisense sequence comprising SEQ ID NO: 2, and wherein said composition induces apoptosis in a variety of cancer cells. 
     
     
         15 . A therapeutic agent comprising a composition comprising siRNA with a sense sequence comprising SEQ ID NO: 3 and an antisense sequence comprising SEQ ID NO: 4, and wherein said composition induces apoptosis in a variety of cancer cells. 
     
     
         16 . The composition according to  claim 14 , wherein said cancer cell is a breast, prostate, colorectal, lung, bladder, colorectal, head and neck, intestine, ovarian, skin or the like. 
     
     
         17 . The composition according to  claim 15 , wherein said cancer cell is a breast, prostate, colorectal, lung, bladder, colorectal, head and neck, intestine, ovarian, skin or the like.